Novo Nordisk, the CEO resigns after the collapse on the stock exchange: -50% in 12 months (two years ago it was the queen of Europe)
In 2023 the Danish pharmaceutical giant had become the major European market company capitalization, overcoming the French luxury group LVMH
Novo Nordisk, the Danish pharmaceutical company known for the treatments for the diabetes and weight lossannounced that the CEO Lars Fruergaard Jorgensen will leave the assignment. The decision comes after the group shares have collapsed by over 50% in the last 12 months.
The announcement of the company
Based on an agreement with the Board of Directors, Jorgensen will continue to play the role of CEO « For the time necessary to support a gradual transition to a new leadership ». « The search for the successor is in progress and an ad will be made public in debt time, » explains the company. The gearbox at the top was decided « in the light of the recent market challenges that Novo Nordisk had to face and the trend of the company’s price from mid -2024 ». A situation that pushed the board of the Novo Nordisk Foundation, which controls the majority of the votes in the assembly, to start a dialogue with the board of Novo Nordisk « on the merits of an accelerated succession of the CEO and expressed the desire to increase its representation on the board of directors of Novo Nordisk ».
The collapse on the bag after the boom
In 2023 Novo Nordiskhad become the major European market for market capitalizationovercoming the French luxury group LVMH. The test results were weighed on the title on a new weight loss drug, which were considered by investors lower than expected, and more recently some ads of the US rival Eli Lilly. In recent days, the American group has announced that its weight loss product recorded results higher than those of Wegovy, the leading therapy of the Danish company. In addition, in April the American pharmaceutical giant had announced the results of a study in phase 3 of its orforgron pill which could be effective how much the popular Mounjaro and Ozempic drugs injectable In lowering the blood sugar level and promoting weight loss in people with type 2 diabetes.
Forecast 2025 Discounted magazines
Last week, the company revised the forecasts for the entire 2025, due to the less than the predictions in the United States of the GLP-1 drug. Novo Nordisk is expected to close the year with an increase in sales between 13% and 21% at constant exchange rates, below 16% -24% previously expected in February. The advertisement of the AD has caused a rain of sale on the stock exchange. The price of the Danish pharmaceutical giant retreats by 4.5% to 414.9 Danish crowns.
:format(jpeg):fill(f8f8f8,true)/s3/static.nrc.nl/wp-content/uploads/2019/10/youp5bij3.png "Column | Cancer Chill – NRC")